277 related articles for article (PubMed ID: 32026157)
41. Assessment of response to anti-angiogenic targeted therapy in pulmonary metastatic renal cell carcinoma: R2* value as a predictive biomarker.
Wu G; Liu G; Kong W; Qu J; Suo S; Liu X; Xu J; Zhang J
Eur Radiol; 2017 Sep; 27(9):3574-3582. PubMed ID: 28130612
[TBL] [Abstract][Full Text] [Related]
42. Comparison of Monoexponential, Biexponential, Stretched-Exponential, and Kurtosis Models of Diffusion-Weighted Imaging in Differentiation of Renal Solid Masses.
Zhang J; Suo S; Liu G; Zhang S; Zhao Z; Xu J; Wu G
Korean J Radiol; 2019 May; 20(5):791-800. PubMed ID: 30993930
[TBL] [Abstract][Full Text] [Related]
43. Diffusion-weighted and multiphase contrast-enhanced MRI as surrogate markers of response to neoadjuvant sunitinib in metastatic renal cell carcinoma.
Bharwani N; Miquel ME; Powles T; Dilks P; Shawyer A; Sahdev A; Wilson PD; Chowdhury S; Berney DM; Rockall AG
Br J Cancer; 2014 Feb; 110(3):616-24. PubMed ID: 24366299
[TBL] [Abstract][Full Text] [Related]
44. CT Intensity Distribution Curve (Histogram) Analysis of Patients Undergoing Antiangiogenic Therapy for Metastatic Renal Cell Carcinoma.
Boos J; Revah G; Brook OR; Rangaswamy B; Bhatt RS; Brook A; Raptopoulos V
AJR Am J Roentgenol; 2017 Aug; 209(2):W85-W92. PubMed ID: 28570097
[TBL] [Abstract][Full Text] [Related]
45. Small (< 4 cm) Renal Tumors With Predominantly Low Signal Intensity on T2-Weighted Images: Differentiation of Minimal-Fat Angiomyolipoma From Renal Cell Carcinoma.
Park JJ; Kim CK
AJR Am J Roentgenol; 2017 Jan; 208(1):124-130. PubMed ID: 27824487
[TBL] [Abstract][Full Text] [Related]
46. First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Ruiz-Morales JM; Swierkowski M; Wells JC; Fraccon AP; Pasini F; Donskov F; Bjarnason GA; Lee JL; Sim HW; Sliwczynsk A; Ptak-Chmielewska A; Teter Z; Beuselinck B; Wood LA; Yuasa T; Pezaro C; Rini BI; Szczylik C; Choueiri TK; Heng DY
Eur J Cancer; 2016 Sep; 65():102-8. PubMed ID: 27487293
[TBL] [Abstract][Full Text] [Related]
47. Comparison of Biexponential and Monoexponential Model of Diffusion-Weighted Imaging for Distinguishing between Common Renal Cell Carcinoma and Fat Poor Angiomyolipoma.
Ding Y; Zeng M; Rao S; Chen C; Fu C; Zhou J
Korean J Radiol; 2016; 17(6):853-863. PubMed ID: 27833401
[TBL] [Abstract][Full Text] [Related]
48. Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors.
Négrier S; Pérol D; Bahleda R; Hollebecque A; Chatelut E; Boyle H; Cassier P; Metzger S; Blanc E; Soria JC; Escudier B
BMC Cancer; 2017 Aug; 17(1):547. PubMed ID: 28810837
[TBL] [Abstract][Full Text] [Related]
49. Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy.
Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
AJR Am J Roentgenol; 2010 Jun; 194(6):1470-8. PubMed ID: 20489085
[TBL] [Abstract][Full Text] [Related]
50. Inter-observer variation and diagnostic efficacy of apparent diffusion coefficient (ADC) measurements obtained by diffusion-weighted imaging (DWI) in small renal masses.
Ponhold L; Javor D; Heinz-Peer G; Sevcenco S; Hofstetter M; Baltzer PA
Acta Radiol; 2016 Aug; 57(8):1014-20. PubMed ID: 26486599
[TBL] [Abstract][Full Text] [Related]
51. C-reactive protein at 1 month after treatment of nivolumab as a predictive marker of efficacy in advanced renal cell carcinoma.
Noguchi G; Nakaigawa N; Umemoto S; Kobayashi K; Shibata Y; Tsutsumi S; Yasui M; Ohtake S; Suzuki T; Osaka K; Muraoka K; Hasumi H; Kondo K; Igarashi Y; Sasada T; Kishida T; Yao M
Cancer Chemother Pharmacol; 2020 Jul; 86(1):75-85. PubMed ID: 32537714
[TBL] [Abstract][Full Text] [Related]
52. Prospective Translational Study Investigating Molecular PrEdictors of Resistance to First-Line PazopanIb in Metastatic reNal CEll Carcinoma (PIPELINE Study).
Sepe P; Martinetti A; Mennitto A; Verzoni E; Claps M; Raimondi A; Sottotetti E; Grassi P; Guadalupi V; Stellato M; Zattarin E; Di Maio M; Procopio G
Am J Clin Oncol; 2020 Sep; 43(9):621-627. PubMed ID: 32889831
[TBL] [Abstract][Full Text] [Related]
53. Whole-Tumor Quantitative Apparent Diffusion Coefficient Histogram and Texture Analysis to Differentiation of Minimal Fat Angiomyolipoma from Clear Cell Renal Cell Carcinoma.
Li H; Li A; Zhu H; Hu Y; Li J; Xia L; Hu D; Kamel IR; Li Z
Acad Radiol; 2019 May; 26(5):632-639. PubMed ID: 30087067
[TBL] [Abstract][Full Text] [Related]
54. Assessment of early therapeutic response to sorafenib in renal cell carcinoma xenografts by dynamic contrast-enhanced and diffusion-weighted MR imaging.
Jeon TY; Kim CK; Kim JH; Im GH; Park BK; Lee JH
Br J Radiol; 2015 Sep; 88(1053):20150163. PubMed ID: 26133222
[TBL] [Abstract][Full Text] [Related]
55. Initial experience with first-line pazopanib in the treatment of metastatic renal cell carcinoma: A single institution data.
Joshi A; Agarwala V; Ramaswamy A; Noronha V; Patil VM; Menon S; Popat P; Sable N; Prabhash K
Indian J Cancer; 2016; 53(4):575-578. PubMed ID: 28485355
[TBL] [Abstract][Full Text] [Related]
56. Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker.
Goh V; Ganeshan B; Nathan P; Juttla JK; Vinayan A; Miles KA
Radiology; 2011 Oct; 261(1):165-71. PubMed ID: 21813743
[TBL] [Abstract][Full Text] [Related]
57. Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study).
Schmidinger M; Bamias A; Procopio G; Hawkins R; Sanchez AR; Vázquez S; Srihari N; Kalofonos H; Bono P; Pisal CB; Hirschberg Y; Dezzani L; Ahmad Q; Jonasch E;
Oncologist; 2019 Apr; 24(4):491-497. PubMed ID: 30867244
[TBL] [Abstract][Full Text] [Related]
58. Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
Miyake H; Imai S; Harada K; Fujisawa M
Clin Genitourin Cancer; 2016 Feb; 14(1):e19-24. PubMed ID: 26382221
[TBL] [Abstract][Full Text] [Related]
59. Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: A pooled secondary analysis of clinical trials.
Sorich MJ; Kichenadasse G; Rowland A; Woodman RJ; Mangoni AA
Int J Cancer; 2016 May; 138(9):2293-9. PubMed ID: 26685869
[TBL] [Abstract][Full Text] [Related]
60. Impact of concomitant acid suppressive therapy on pazopanib efficacy and dose reductions in patients with metastatic renal cell carcinoma.
Van De Sijpe G; Beuselinck B; Van Nieuwenhuyse T; Poncelet R; Bechter O; Albersen M; Roussel E; Baldewijns M; Tack J; Spriet I
Eur J Clin Pharmacol; 2020 Sep; 76(9):1273-1280. PubMed ID: 32474662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
